Your browser is no longer supported. Please, upgrade your browser.
Settings
GHDX Genomic Health Inc. daily Stock Chart
GHDX [NASD]
Genomic Health Inc.
Index- P/E- EPS (ttm)-1.14 Insider Own0.50% Shs Outstand32.54M Perf Week-11.28%
Market Cap839.86M Forward P/E- EPS next Y-0.13 Insider Trans-16.49% Shs Float31.56M Perf Month-19.60%
Income-36.80M PEG- EPS next Q-0.09 Inst Own95.50% Short Float4.63% Perf Quarter-3.15%
Sales281.50M P/S2.98 EPS this Y-85.70% Inst Trans-0.62% Short Ratio5.40 Perf Half Y4.62%
Book/sh4.08 P/B6.33 EPS next Y87.40% ROA-19.40% Target Price33.96 Perf Year-14.28%
Cash/sh3.01 P/C8.57 EPS next 5Y- ROE-25.20% 52W Range20.05 - 35.79 Perf YTD-26.68%
Dividend- P/FCF- EPS past 5Y-18.80% ROI-16.50% 52W High-27.88% Beta0.53
Dividend %- Quick Ratio3.30 Sales past 5Y13.00% Gross Margin81.50% 52W Low28.73% ATR1.79
Employees752 Current Ratio3.30 Sales Q/Q6.50% Oper. Margin-13.10% RSI (14)33.65 Volatility6.65% 5.85%
OptionableYes Debt/Eq0.00 EPS Q/Q-80.00% Profit Margin-13.10% Rel Volume1.12 Prev Close26.72
ShortableYes LT Debt/Eq0.00 EarningsFeb 10 AMC Payout- Avg Volume270.28K Price25.81
Recom2.40 SMA20-13.01% SMA50-16.66% SMA200-4.60% Volume302,696 Change-3.41%
Feb-11-16Reiterated Canaccord Genuity Buy $44 → $38
Jan-11-16Downgrade Piper Jaffray Overweight → Neutral
Jan-07-16Reiterated Barclays Underweight $25 → $27
Jan-06-16Upgrade Canaccord Genuity Hold → Buy $26 → $44
Nov-23-15Upgrade UBS Neutral → Buy $29 → $38
Nov-04-15Upgrade Raymond James Mkt Perform → Outperform
Sep-02-15Initiated Barclays Underweight $25
Aug-28-15Upgrade Raymond James Underperform → Mkt Perform
Aug-05-15Reiterated Canaccord Genuity Hold $28 → $26
Mar-10-15Initiated UBS Neutral $34
Aug-11-14Reiterated Canaccord Genuity Hold $30 → $27
Aug-02-13Reiterated MLV & Co Hold $30 → $35
Feb-21-12Downgrade GARP Research Buy → Neutral
Feb-08-12Downgrade MLV & Co Buy → Hold $31.50 → $30
Dec-12-11Reiterated Ladenburg Thalmann Buy $26 → $32
Nov-02-11Upgrade Ladenburg Thalmann Neutral → Buy $26
Oct-11-11Reiterated RBC Capital Mkts Sector Perform $27 → $21
Oct-05-11Initiated Oppenheimer Perform $20
Feb-09-11Downgrade Ladenburg Thalmann Buy → Neutral
Nov-16-10Initiated Canaccord Genuity Hold $19
Feb-11-16 02:20PM  Genomic Health, Inc. Eyes Profitability at Motley Fool
12:10PM  Genomic Health Q4 Loss Wider than Expected, Revenues Up
12:11AM  Edited Transcript of GHDX earnings conference call or presentation 10-Feb-16 9:30pm GMT
Feb-10-16 05:55PM  Genomic Health reports 4Q loss
04:12PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:05PM  Genomic Health Announces 2016 Financial Outlook and Provides 2015 Fourth Quarter and Year-End Financial Results PR Newswire
07:07AM  Q4 2015 Genomic Health Inc Earnings Release - After Market Close
Feb-08-16 07:40PM  The One Question for Genomic Health, Inc. at Motley Fool
Feb-03-16 08:00AM  Genomic Health to Announce Fourth Quarter and Year-End 2015 Financial Results and Host Conference Call on Wednesday, February 10, 2016 PR Newswire
Jan-19-16 12:15PM  Genomic Health, Inc. Value Analysis (NASDAQ:GHDX) : January 19, 2016
Jan-18-16 08:06AM  Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : January 18, 2016
Jan-13-16 09:25AM  Day 3 of #JPM16: Low-risk hookups vs. big-dollar tie-ups, seat gouging and the space race at bizjournals.com
Jan-11-16 02:40PM  Genomic Health Down on Bleak Preliminary Q4, '15 Results
10:24AM  Day 1 of #JPM16: Liquid biopsies, rare diseases and off-the-record keynotes at bizjournals.com
08:00AM  Genomic Health Announces Plans to Launch Liquid Biopsy Mutation Panel in 2016 PR Newswire
06:26AM  Genomic Health downgraded by Piper Jaffray
Jan-08-16 08:05AM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
08:00AM  Genomic Health Announces Preliminary 2015 Revenue and Confirms 2016 Growth Expectations PR Newswire
Jan-06-16 02:11PM  Genomic Health Upgraded By Canaccord, $44 Per Share Target Predicted
Jan-04-16 08:00AM  Genomic Health to Present at the 34th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-21-15 08:00AM  Genomic Health (GHDX) Shows Strength: Stock Gains 8.2% +5.74%
Dec-19-15 10:36AM  Last Week's Best Healthcare ETF at Motley Fool
Dec-15-15 04:05PM  New "Big Data" Brings Total Number of Breast Cancer Patients Studied to 50,000, Demonstrating Oncotype DX® Accurately Predicts Clinical Outcomes PR Newswire
Dec-10-15 09:38AM  November's Best Healthcare ETF at Motley Fool
Dec-09-15 08:00AM  Genomic Health Announces Presentation of Eight Oncotype DX® Studies at the 2015 CTRC-AACR San Antonio Breast Cancer Symposium PR Newswire
Dec-08-15 01:17PM  GENOMIC HEALTH INC Financials
Nov-22-15 08:16PM  Is Genomic Health, Inc. (GHDX) A Good Stock To Buy? at Insider Monkey
Nov-20-15 08:06AM  Genomic Health Led IBBs Healthcare Subgroup
Nov-19-15 01:31PM  Genomic Health: A Prostate Play Helping Investors Get Ahead Of The Curve?
Nov-18-15 04:29PM  Medical test makers win higher rates from feds, stocks rebound at bizjournals.com
08:00AM  CMS Releases Final 2016 Clinical Lab Fee Schedule (CLFS) Including Gap-fill Pricing for Oncotype DX® Colon Cancer Test PR Newswire
Nov-16-15 08:00AM  Genomic Health Announces Presentation of Eight Oncotype DX® Studies at the 2015 CTRC-AACR San Antonio Breast Cancer Symposium PR Newswire
Nov-11-15 05:32PM  Genomic Health Overseas Business Strong, Margin Woes Stay
Nov-09-15 06:27PM  GENOMIC HEALTH INC Files SEC form 10-Q/A, Quarterly Report
Nov-07-15 09:20AM  Genomic Health, Inc. on Path to Profitability at Motley Fool
Nov-05-15 05:59PM  GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report
02:37PM  Genomic Health, Inc. Value Analysis (NASDAQ:GHDX) : November 5, 2015
10:19AM  Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : November 5, 2015
08:00AM  Genomic Health (GHDX) Shows Strength: Stock Gains 18.6%
Nov-04-15 08:49PM  Biz Break: Facebook sets records for share price and users at San Jose Mercury News +18.58%
02:00PM  Genomic Health Q3 Loss Wider than Expected, '15 View Kept
01:55PM  Here's Why Genomic Health, Inc. Popped Today at Motley Fool
02:29AM  Edited Transcript of GHDX earnings conference call or presentation 3-Nov-15 9:30pm GMT
Nov-03-15 05:05PM  Genomic Health reports 3Q loss
04:30PM  Genomic Health Inc Earnings Call scheduled for 4:30 pm ET today
04:12PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:05PM  Genomic Health Reports Highest Test Growth in Two Years in Announcement of Third Quarter 2015 Financial Results PR Newswire
08:00AM  Genomic Health to Present at Two Upcoming Investor Conferences PR Newswire
07:07AM  Q3 2015 Genomic Health Inc Earnings Release - After Market Close
Oct-27-15 08:00AM  Genomic Health to Announce Third Quarter 2015 Financial Results and Host Conference Call on Tuesday, November 3, 2015 PR Newswire
Oct-16-15 03:56PM  Medicare Initiates Coverage on Genomic Prostate Cancer Test
09:00AM  CMS Hikes Medicare Rate for Genomic's Breast Cancer Test (Revised)
Oct-15-15 04:30PM  Medicare Initiates Coverage for Genomic Health's Oncotype DX® Prostate Cancer Test Effective Immediately PR Newswire
Oct-13-15 04:25PM  Philips Equips Pathologists with New Digitalized Services
02:50PM  CMS Hikes Medicare Rate for Genomic's Breast Cancer Test
Oct-12-15 08:00AM  Philips teams up with Genomic Health to utilize innovative digital pathology solutions to optimize pre-analytical specimen processing PR Newswire
Oct-07-15 08:00AM  CMS Increases Final Pricing Determination for Oncotype DX® Breast Cancer Test to Previously Established Rate of $3,416 PR Newswire +6.40%
Sep-29-15 04:25PM  Feds to diagnostics companies: We're here to help (you lose money) at bizjournals.com
11:45AM  Key Analyst Sees Opportunity in Diagnostics Sell-Off at 24/7 Wall St.
Sep-28-15 02:00PM  Genomic Health Posts Positive Breast Cancer Trial Results
01:08PM  Gene Test Helps Some Breast-Cancer Patients Skip Chemo at The Wall Street Journal
01:08PM  Gene Test Helps Some Breast-Cancer Patients Skip Chemo, Study Says at The Wall Street Journal
08:00AM  Genomic Health Responds to Flawed CMS Gap-fill Pricing for Oncotype DX® Breast Cancer Test PR Newswire
07:30AM  TAILORx trial finds 99% of women with low Oncotype DX® Recurrence Score® are free of breast cancer recurrence after five years of hormone therapy alone PR Newswire
07:30AM  TAILORx trial finds 99% of women with low Oncotype DX® Recurrence Score® are free of breast cancer recurrence after five years of hormone therapy alone CNW Group
01:39AM  Gene test finds which breast cancer patients can skip chemo
01:15AM  Two Large International Studies Provide Additional Prospective Data Reinforcing the Ability of Oncotype DX® to Accurately Predict Clinical Outcomes in Early-Stage Breast Cancer Patients PR Newswire
01:15AM  TAILORx trial finds 99 percent of women with low Oncotype DX® Recurrence Score® are free of breast cancer recurrence after five years of hormone therapy alone PR Newswire
Sep-11-15 02:20PM  Genomic Health: Test Volume Impresses, Margin Woes Persist
08:00AM  Multiple Oncotype DX® Outcomes Studies, Including Results from NCI-sponsored TAILORx Breast Cancer Trial, to be Presented at 2015 European Cancer Congress PR Newswire
Sep-08-15 04:05PM  A Portfolio To Support Cancer Treatments In Time For Prostate Cancer Awareness Month
Aug-25-15 11:29AM  Genomic Health, Inc. Q2 Earnings, 2015
Aug-20-15 08:00AM  Breast Cancer Research and Treatment Publishes Oncotype DX(R) DCIS Score(TM) Study Conducted in Canada PR Newswire -6.41%
08:00AM  Breast Cancer Research and Treatment Publishes Oncotype DX(R) DCIS Score(TM) Study Conducted in Canada CNW Group
Aug-18-15 01:55PM  Genomic Health Prostate Cancer Test Wins Medicare Coverage
Aug-17-15 08:00AM  Genomic Health's Oncotype DX® Prostate Cancer Test Receives Medicare Coverage PR Newswire +7.81%
Aug-08-15 08:10PM  10-Q for Genomic Health, Inc. at Company Spotlight
Aug-06-15 05:47PM  GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report
10:50AM  Genomic Health Q2 Loss Wider than Expected; Tests Ramp Up - Analyst Blog
Aug-04-15 11:30PM  Edited Transcript of GHDX earnings conference call or presentation 4-Aug-15 8:30pm GMT
09:00PM  Still Waiting for Profitability at Genomic Health at Motley Fool
05:30PM  Genomic Health reports 2Q loss
04:30PM  Genomic Health Inc Earnings Call scheduled for 4:30 pm ET today
04:23PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:07PM  Genomic Health Announces Second Quarter 2015 Financial Results and Reports Record International and Prostate Cancer Tests Delivered PR Newswire
07:07AM  Q2 2015 Genomic Health Inc Earnings Release - After Market Close
Jul-31-15 08:57PM  3 Things to Watch as Genomic Health Reports Earnings at Motley Fool
Jul-30-15 08:00AM  Urology Practice Publishes Study Showing Oncotype DX® Increases Use of Active Surveillance in Prostate Cancer Patients by 56 Percent PR Newswire
Jul-29-15 01:30PM  Salesforce.com Aims at Regulated Industries at Investopedia
Jul-28-15 08:00AM  Genomic Health to Announce Second Quarter 2015 Financial Results and Host Conference Call on Tuesday, August 4, 2015 PR Newswire
Jul-14-15 08:00AM  Breast Cancer Research and Treatment Publishes Oncotype DX® DCIS Score Study PR Newswire
Jul-13-15 01:30PM  MTST: Zacks Small Cap Research Initiates Coverage of MTST at Buy
Jun-25-15 02:20PM  Genomic's Oncotype DCIS Score Betters Treatment Guidance - Analyst Blog
Jun-23-15 11:55AM  Healthcare-Focused Fund Camber Capitals Top Picks: Masimo Corporation (MASI), The Medicines Company (MDCO) at Insider Monkey
08:00AM  Journal of Surgical Oncology Publishes Study Showing Oncotype DX® DCIS Score Result Changes Treatment Recommendations in 30 Percent of DCIS Breast Cancer Patients PR Newswire
Jun-17-15 04:03PM  GENOMIC HEALTH INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
02:30PM  Genomic Health Liquid Biopsy Test Fit for Bladder Cancer - Analyst Blog
Jun-16-15 08:00AM  Genomic Health Presents Positive Proof-of-Concept Data for Bladder Cancer Liquid Biopsy Test PR Newswire
Jun-12-15 04:49AM  Edited Transcript of GHDX earnings conference call or presentation 5-May-15 8:30pm GMT
Jun-11-15 08:00AM  Genomic Health to Present Proof-of-Concept Bladder Cancer Liquid Biopsy Data at AACR Precision Medicine Meeting PR Newswire
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; and Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading. Genomic Health, Inc. was founded in 2000 and is based in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vaughn James JChief Commercial OfficerFeb 09Option Exercise18.8935724,079Feb 11 04:24 PM
Vaughn James JChief Commercial OfficerFeb 09Sale28.0038424,076Feb 11 04:24 PM
LIVINGSTON RANDALL SDirectorJan 13Option Exercise10.731,25013,4137,399Jan 15 05:17 PM
LIVINGSTON RANDALL SDirectorJan 13Sale32.141,25040,1756,149Jan 15 05:17 PM
Cole G BradleyCOOJan 12Option Exercise18.894,00075,56031,428Jan 14 04:56 PM
Cole G BradleyCOOJan 12Sale31.694,000126,77127,428Jan 14 04:56 PM
Vaughn James JChief Commercial OfficerJan 07Option Exercise18.892,00037,78026,076Jan 08 04:13 PM
Vaughn James JChief Commercial OfficerJan 07Sale33.632,00067,26524,076Jan 08 04:13 PM
Popovits Kimberly JPresident and CEODec 15Option Exercise18.895,00094,45040,691Dec 17 04:47 PM
Popovits Kimberly JPresident and CEODec 15Sale30.005,000150,00035,691Dec 17 04:47 PM
Vaughn James JChief Commercial OfficerDec 07Option Exercise18.892,00037,78026,076Dec 09 03:02 PM
Leber LauraChief Communication OfficerDec 07Option Exercise10.154,20042,63017,159Dec 09 03:03 PM
Leber LauraChief Communication OfficerDec 07Sale29.334,200123,20212,959Dec 09 03:03 PM
Vaughn James JChief Commercial OfficerDec 07Sale29.332,00058,66824,076Dec 09 03:02 PM
Cole G BradleyCOONov 10Option Exercise18.894,00075,56034,326Nov 12 04:08 PM
Cole G BradleyCOONov 10Sale26.034,000104,12830,326Nov 12 04:08 PM
Cole G BradleyCOOSep 09Option Exercise9.393,66434,40533,990Sep 10 04:38 PM
Cole G BradleyCOOSep 09Sale25.403,66493,05630,326Sep 10 04:38 PM
Cole G BradleyCOOSep 08Option Exercise9.396,00056,34036,326Sep 10 04:38 PM
Cole G BradleyCOOSep 08Sale25.326,000151,92930,326Sep 10 04:38 PM
Cole G BradleyCOOJul 07Option Exercise9.394,00037,56034,326Jul 09 07:25 PM
Cole G BradleyCOOJul 07Sale27.534,000110,11230,326Jul 09 07:25 PM
Cole G BradleyCOOJun 09Option Exercise9.394,00037,56034,326Jun 11 05:34 PM
Cole G BradleyCOOJun 09Sale26.244,000104,96530,326Jun 11 05:34 PM
Cole G BradleyCOOMay 12Option Exercise9.394,00037,56033,658May 14 04:51 PM
Cole G BradleyCOOMay 12Sale27.544,000110,15729,658May 14 04:51 PM
Popovits Kimberly JPresident and CEOApr 13Option Exercise18.893,00056,67037,939Apr 15 04:57 PM
Popovits Kimberly JPresident and CEOApr 13Sale31.283,00093,84034,939Apr 15 04:57 PM
Cole G BradleyCOOApr 07Option Exercise9.394,00037,56033,658Apr 09 04:16 PM
Cole G BradleyCOOApr 07Sale30.444,000121,74729,658Apr 09 04:16 PM
Popovits Kimberly JPresident and CEOMar 12Option Exercise18.893,00056,67037,939Mar 17 05:50 PM
Popovits Kimberly JPresident and CEOMar 12Sale31.913,00095,71734,939Mar 17 05:50 PM
Cole G BradleyCOOMar 10Option Exercise9.394,00037,56033,658Mar 12 04:05 PM
Cole G BradleyCOOMar 10Sale31.844,000127,37629,658Mar 12 04:05 PM
Popovits Kimberly JPresident and CEOFeb 12Option Exercise18.893,00056,67039,965Feb 17 07:12 PM
Popovits Kimberly JPresident and CEOFeb 12Sale29.863,00089,56636,965Feb 17 07:12 PM